Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression

Journal of B.U.ON.

Volumn 15, Issue 4, 2010, Pages 774-782

  Demir, Hale ^a   Turna, H ^a   Can, G ^a   Ilvan, S ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Basal like type; Breast carcinoma; GATA3; Molecular classification

Indexed keywords

CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR GATA 3;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TISSUE MICROARRAY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; IMMUNOENZYME TECHNIQUES; KERATINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78651385364     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Sortie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
2. Sortie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
3. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
4. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-271.
5. Callagy G, Cattaneo E, Daigo Y et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003; 12: 27-34.
6. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006; 37: 1217-1226.
7. Ihemelandu CU, Leffall LD Jr, Dewitty RL et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 2007; 143: 109-118.
8. Wiechmann L, Sampson M, Stempel M et al. Presenting Features of Breast Cancer Differ by Molecular Subtype. Ann Surg Oncol 2009; 16: 2705-2710.
9. Zhao J, Liu H, Wang M et al. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol 2009; 100: 89-94.
10. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376.
11. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004; 203: 661-671.
12. Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol 2008; 39: 167-174.
13. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005; 447: 688-694.
14. Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev 2008; 17: 365-373.
15. Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 2007; 67: 6477-6483.
16. Hoch RV, Thompson DA, Baker RJ, Weigel RJ. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 1999; 84: 122-128.
17. Parikh P, Palazzo JP, Rose LJ, Daskalakis C, Weigel RJ. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg 2005; 200: 705-710.
18. Jacquemier J, Charafe-Jauffret E, Monville F et al. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res 2009; 11: R23.
19. Albergaria A, Paredes J, Sousa B et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res 2009; 11: R40.
20. American Joint Committee on Cancer. Comparison Guide: Cancer Staging manual, fifth versus sixth edition. www.cancerstaging.org. 2008; 20-23.
21. Ellis IO, Schnitt SJ, Sastre-Gerau X et al. Invasive Breast Carcinoma. In: Tavassoli FA, Devielee P (Eds): Tumours of the Breast and Female Genital Organs, WHO Classification. IARC Press, Lyon, 2003, pp 11-59.
22. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
23. Ge Y, Sneige N, Eltorky MA et al. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res 2009; 11: R28.
24. Lin CH, Liau JY, Lu YS et al. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev 2009; 18: 1807-1814.
25. Andea AA, Bouwman D, Wallis T, Visscher DW. Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer 2004; 100: 20-27. (Pubitemid 37553535)
26. Kusinska R, Potemski P, Jesionek-Kupnicka D, Kordek R. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma - relation with grade, stage, estrogen receptor and HER2. Pol J Pathol 2005; 56: 107-110.
27. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
28. Lester SC. The Female Breast: Prognostic and Predictive Factors. In: Kumar V, Abbas AK, Fausto N (Eds): Robins and Kotran Pathologic Basis of Disease (7th Edn). Saunders, Philadelphia 2005, pp 1146-1148.